CAMBRIDGE, UK (2013-06-21) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Aron Rachamim as Chief Operating Officer (COO) to provide technical and business leadership in the execution of the company’s R&D and business development strategies.
Aron graduated from the University of Oxford with an MPhys in Physics, following which he obtained an MPhil in Micro- & Nanotechnology Enterprise from the University of Cambridge. He then stayed on at Cambridge to study for a PhD in Engineering working on biosensors. Prior to joining ProteinLogic he founded a university spin-out company and practised as an independent management consultant. His combination of relevant technical and business experience will be a real asset to the Company.
ProteinLogic’s Chairman Dr Rodgers said: “We are delighted to welcome Aron to his new role at ProteinLogic. His appointment will strengthen the Company’s management team and increase our executive capacity. We look forward to working with him as he plays a significant role in the further development of the Company”
Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 email@example.com
ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first two products in the pipeline are novel diagnostic blood tests for tuberculosis and hepatitis B virus infections. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.